SecBot SecBot
SECBOTREPLAY Home › Report › KALV

KALV · Multiple C-suite executives at KalVista Pharmaceuticals (KALV) sold…

KalVista Pharmaceuticals, Inc. · CLUSTER filed Feb 22, 2026 at 19:00 ET

At the news

BEARISHIMPACT 6/10

CLUSTER filed Feb 22, 2026 at 19:00 ET

Multiple C-suite executives at KalVista Pharmaceuticals (KALV) sold shares in a concentrated 7-day window, including the Chief Development Officer, CFO, and Chief Commercial Officer, realizing over $157,000 in total proceeds. The transactions include both cash sales and share movements (M) with no stated value, suggesting possible pre-arranged 10b5-1 plans or equity settlements. The cluster of insider selling by top executives raises caution despite lack of explicit negative filing disclosures.

  • Chief Development Officer Christopher Yea sold 4,347 shares for $67,669.
  • CFO Brian Piekos sold 1,767 shares for $27,507.
  • Chief Commercial Officer Nicole Sweeny sold 3,975 shares for $61,878.
  • Total cash proceeds from insider sales: $157,054.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access